Novartis announces NEJM publication of updated analysis from ELIANA trial showing longer-term durable remissions with Kymriah(TM) in children, young adults with r/r ALL

Analysis of 75 patients with median follow-up of more than a year demonstrated an overall remission rate of 81% Event-free survival and overall survival at six months were 73% and 90%, with median duration of remission not reached Kymriah was detected in patients up to 20 months, demonstrating long-term persistence Novartis is committed to bringing […]